News

Ophthalmology Times35m
3 Things You Should Know About the GA Pipeline
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...
Ophthalmology Times1h
The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...
Ophthalmology Times1h
ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye ...
Ophthalmology Times3h
ARVO 2025: Shortened, maintained, or extended dosing intervals through 96 weeks in PHOTON
At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg ...
Ophthalmology Times9h
Q&A: Priya S. Vakharia, MD, shares insight into the Phase 2 ARCHER trial for GA
Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and ...
Ophthalmology Times9h
Post hoc analysis of GATHER1 and GATHER2 data
New analysis reveals the ellipsoidal zone's role in predicting geographic atrophy progression, enabling timely interventions ...